(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 16.64% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Ani Pharmaceuticals's revenue in 2026 is $883,366,000.On average, 10 Wall Street analysts forecast ANIP's revenue for 2026 to be $24,017,140,728, with the lowest ANIP revenue forecast at $17,119,669,071, and the highest ANIP revenue forecast at $26,057,812,816. On average, 10 Wall Street analysts forecast ANIP's revenue for 2027 to be $28,120,909,872, with the lowest ANIP revenue forecast at $25,003,839,320, and the highest ANIP revenue forecast at $30,654,931,256.
In 2028, ANIP is forecast to generate $31,237,980,424 in revenue, with the lowest revenue forecast at $26,304,487,464 and the highest revenue forecast at $36,373,298,096.